Hematology/Oncology/BMT

Short Name	*Comments*	*Type*	*Investigator*	*Contact*
BMT Cord Blood Access Protocol	**A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) in Pediatric and Adult Patients with Hematologic Malignancies and other Indications** *This is an access study in which umbilical cord blood used for bone marrow transplant is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study.* For More Information	Symptom Management	Dr. Troy Quigg	**Laura Paulsen** Laura.Paulsen@spectrumhealth.org 616.486.6125
NYBB UCB	**A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients** *Umbilical cord blood used for bone marrow transplant which is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study.*	Treatment	Dr. Troy Quigg	**Laura Paulsen** Laura.Paulsen@spectrumhealth.org 616.486.6125
BMT CTN 1507	**Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease** *This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.* For more information…	Treatment	Dr. Ulrich Duffner	**Laura Paulsen** Laura.Paulsen@spectrumhealth.org 616.486.6125

ENDRAD	**The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL**	Treatment	Dr. Ulrich Duffner	**Laura Paulsen** Laura.Paulsen@spectrumhealth.org 616.486.6125
	This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be foll For more information…			
17-SIBS	**Identifying Predictors of Poor Health-Related Quality-of-Life among Pediatric Hematopoietic Stem Cell Donors**	Observational	Dr. Troy Quigg	**Zak Mulder** zachary.mulder@spectrumhealth.org 616.391.2724
	This study will evaluate the long-term quality of life of sibling pediatric HSC donors in comparison to that of healthy non-donor siblings, siblings of children with similar diseases who receive alternate treatments, and healthy age, gender, and race/ethnicity-matched controls.			
NMTRC012 - PEDS-PLAN	**Pediatric Precision Laboratory Advanced Neuroblastoma Therapy**	Treatment	Dr. Deanna Mitchell	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163
	A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma			

HEAD START 4 PROTOCOL	**Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors.** *Clinical and Molecular Rish-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to Either Single-Cycle or to Three Sequential Cycles of Marrow-Ablativ Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue*	Treatment	Dr. Albert Cornelius	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163 **Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
	A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma	Treatment	Dr. Rebecca Loret de Mola	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163 **Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
NMTRC 014-NMTT	**NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)**	Treatment	Dr. Deanna Mitchell	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163